Intellipharmaceutics International Inc. (IPCI)

[fabius]

Angelo,
CNAT deal looks very similar to what you several times suggested could be the structure for IPCI partnership, right ?

"Conatus to get upfront payment of $50m within 5 business days from Novartis for exclusive option to develop products containing emricasan for liver cirrhosis or liver fibrosis.
Upon exercise of option, Conatus will grant Novartis exclusive, worldwide license to emricasan, at which point Conatus would receive $7m; option expires Oct. 31, 2017
Conatus is eligible to receive up to $650m in milestone payments over term of agreement
Option exercisable upon, among other things, Conatus providing notice to Novartis of initiation of planned Phase 2b trial expected in 2Q 2017"